|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ISRCTN |
|
Last refreshed on:
|
13 January 2015 |
|
Main ID: |
ISRCTN27362692 |
|
Date of registration:
|
23/02/2006 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Intranasal zolmitriptan is effective and well tolerated in acute cluster headache
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
01/09/2003 |
|
Target sample size:
|
90 |
|
Recruitment status: |
Completed |
|
URL:
|
http://isrctn.com/ISRCTN27362692 |
|
Study type:
|
Interventional |
|
Study design:
|
Randomised, placebo-controlled, double-blind cross-over trial (Treatment)
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Germany
|
Italy
|
United Kingdom
| | | | | |
|
Contacts
|
|
Name:
|
Peter
Goadsby |
|
Address:
|
Institute of Neurology
University College London
WC1N 3BG
London
United Kingdom |
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Cluster headache with attacks longer than 45 minutes.
Exclusion criteria: Contraindications to zolmitriptan in participating countries.
Age minimum:
Age maximum:
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
Cluster headache
Signs and Symptoms
Headache
|
|
Intervention(s)
|
|
Zolmitriptan nasal spray versus placebo.
|
|
Primary Outcome(s)
|
|
Proportion of patients who have taken active drug with headache relief at 30 minutes.
|
|
Secondary Outcome(s)
|
|
Pain free at 30 minutes.
|
|
Source(s) of Monetary Support
|
|
AstraZeneca (UK)
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|